Seagen quietly doles out cell therapy patent rights, but scope remains unclear
16 Mar 2023
License out/inCell TherapyAcquisition
On the heels
of its $43 billion buyout by Pfizer
, Seagen is slimming its cell therapy efforts.
The big biotech signed a licensing deal with Gracell Biotechnologies last week, granting the smaller partner rights to certain patents,
SEC documents show
. Gracell will conduct preclinical and clinical research on the unnamed cell therapy programs and be able to bring up to five to the market.
The scope of Thursday’s deal and content of the Seagen patents, however, remain a mystery for now. Neither company issued a press release about the deal and no financial terms were disclosed in the SEC filings. Representatives for Seagen and Gracell did not immediately respond to requests for comment.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.